Form 4: LivaNova Director William Kozy Reports Routine Share Transactions and New RSU Grant

LivaNova PLC Director William A. Kozy reported the settlement of vested restricted stock units, the sale of shares to cover tax liabilities, and the grant of new restricted stock units, as detailed in a recent SEC Form 4 filing.

Summary

• Director William A. Kozy acquired 4,840 ordinary shares of LivaNova PLC from the settlement of vested restricted stock units (RSUs) under the Company's 2015 Incentive Award Plan.
• Concurrently, 581 ordinary shares were disposed of at a price of $45.76 per share to satisfy tax liabilities associated with the RSU vesting.
• Following these transactions, Mr. Kozy's direct beneficial ownership of LivaNova ordinary shares stands at 32,567.
• Additionally, Mr. Kozy was granted 5,681 new Restricted Stock Units (RSUs) under the Company's 2025 Director Incentive Award Plan.
• These newly granted RSUs are scheduled to vest on June 15, 2026, contingent upon Mr. Kozy's continued service during the vesting period.

Sentiment

Score: 7

Explanation: The filing details routine insider transactions related to executive compensation, including RSU vesting and a new RSU grant, which are standard practices and do not indicate significant positive or negative operational news. The continued equity alignment is a minor positive.

Positives

• Director Kozy received a significant number of shares (4,840) from vested RSUs, indicating the successful payout of long-term incentive compensation.
• The grant of 5,681 new Restricted Stock Units aligns the director's future interests with long-term shareholder value and retention.

Negatives

• A portion of the vested shares (581) was sold to cover tax liabilities, resulting in a reduction of direct shareholding, though this is a common practice.

Future Outlook

The grant of new Restricted Stock Units vesting in June 2026 indicates continued alignment of the director's incentives with the company's long-term performance and continued service.

Industry Context

This Form 4 filing details routine insider transactions, which are common in publicly traded companies across all industries, including the medical technology sector where LivaNova PLC operates. Such filings provide transparency into executive and director compensation practices.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of director compensation is a standard practice across publicly traded companies, particularly within the medical device and healthcare sectors, to align the interests of directors with those of shareholders.
• The sale of shares to cover tax liabilities upon RSU vesting is also a common and expected occurrence in equity compensation plans.
• Specific comparable companies, projects, or results are not detailed within this Form 4 filing, as its purpose is to report individual insider transactions rather than provide industry-wide performance benchmarks.

Related Party Transactions

• Settlement of 4,840 vested Restricted Stock Units to Director William A. Kozy under the 2015 Incentive Award Plan.
• Grant of 5,681 new Restricted Stock Units to Director William A. Kozy under the 2025 Director Incentive Award Plan.

Stakeholder Impact

• Shareholders: The director's continued equity ownership and the grant of new RSUs align his interests with long-term shareholder value creation.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• Vesting of 5,681 Restricted Stock Units on June 15, 2026, subject to continued service by Director William A. Kozy.

Key Dates

Recommendation

Keywords

LivaNova PLC, LIVN, Form 4, Insider Trading, Director Shareholding, Restricted Stock Units, RSU, Executive Compensation, Share Transactions